Curated News
By: NewsRamp Editorial Staff
July 16, 2025
Kairos Pharma to Showcase Cancer Breakthroughs at H.C. Wainwright Conference
TLDR
- Kairos Pharma's participation in the H.C. Wainwright conference offers investors a unique opportunity to gain insights into its innovative cancer therapeutics and potential market advantages.
- Kairos Pharma will present at the H.C. Wainwright conference, detailing its ENV105 antibody's mechanism to target CD105 and reverse drug resistance in cancer treatments.
- Kairos Pharma's research into ENV105 could revolutionize cancer treatment by overcoming drug resistance, offering hope for patients with castrate resistant prostate and lung cancers.
- Discover how Kairos Pharma's ENV105 is tackling cancer drug resistance, a breakthrough that could change the future of oncology treatment.
Impact - Why it Matters
This news is crucial for investors, healthcare professionals, and patients alike, as it underscores the potential of Kairos Pharma's ENV105 to revolutionize cancer treatment by addressing the pervasive issue of drug resistance. The company's participation in a prestigious investment conference also signals its growing prominence in the biopharmaceutical sector, offering hope for more effective cancer therapies in the near future.
Summary
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, is set to make a significant appearance at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025, in New York City. The company will engage in one-on-one meetings and present its latest developments, accessible virtually through kairospharma.com. This event highlights Kairos Pharma's commitment to advancing its innovative cancer treatments, including its lead candidate, ENV105, which targets CD105 to combat drug resistance in cancer therapy. ENV105 is currently undergoing Phase 2 and Phase 1 clinical trials for castrate-resistant prostate cancer and lung cancer, respectively, addressing critical gaps in cancer treatment.
For those interested in the full details of Kairos Pharma's participation and its groundbreaking work in oncology, the press release is available at https://ibn.fm/s0U0R. Kairos Pharma's approach to overcoming drug resistance and immune suppression in cancer through structural biology positions it as a leader in the next generation of cancer therapeutics. More information about their pioneering research can be found on their website at www.KairosPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma to Showcase Cancer Breakthroughs at H.C. Wainwright Conference
